Can pregabalin (Lyrica) be prescribed with cyclobenzaprine (Flexeril)?

Can Lyrica (Pregabalin) Be Prescribed with Flexeril (Cyclobenzaprine)?

Yes, pregabalin (Lyrica) can be prescribed with cyclobenzaprine (Flexeril), as there are no documented pharmacokinetic drug interactions between these medications, though clinicians must monitor closely for additive central nervous system (CNS) depression effects.

Pharmacological Compatibility

Pregabalin has minimal drug interaction potential because it:

• Is predominantly excreted unchanged in urine (>98%)
• Undergoes negligible metabolism (<2%)
• Does not bind to plasma proteins
• Does not affect cytochrome P450 enzymes 1

The FDA label explicitly states that pregabalin is "unlikely to be involved in significant pharmacokinetic drug interactions" 1. Population pharmacokinetic studies confirm pregabalin does not alter steady-state concentrations of multiple co-administered medications 2.

Cyclobenzaprine is a centrally acting 5-HT2 receptor antagonist structurally related to amitriptyline 3. While it has anticholinergic properties and can interact with sedatives and anesthetic agents 3, there is no documented pharmacokinetic interaction with pregabalin.

Critical Safety Considerations

Additive CNS Depression (Primary Concern)

Both medications cause dose-dependent sedation and dizziness 4. The FDA label warns that when pregabalin is co-administered with CNS depressants like opioids or lorazepam, "additive effects on cognitive and gross motor functioning were seen" 1. While this specific warning doesn't mention cyclobenzaprine, the same principle applies.

Monitor for:

• Excessive somnolence (pregabalin causes this in 35.7% of patients vs 11.5% placebo) 1
• Dizziness (20.9% vs 6.9% placebo) 1
• Impaired coordination and falls risk
• Confusion, particularly in elderly patients

Serotonin Syndrome Risk

Cyclobenzaprine has serotonergic activity and can cause serotonin syndrome when combined with other serotonergic drugs 5. While pregabalin is not primarily serotonergic, exercise caution if the patient is taking additional serotonergic medications (SSRIs, SNRIs, MAOIs). The combination of cyclobenzaprine with duloxetine or phenelzine has caused severe serotonin syndrome 5.

Anticholinergic Effects

Cyclobenzaprine produces anticholinergic effects including:

• Confusion and hallucinations
• Urinary retention
• Constipation
• Dry mouth 3

When combined with pregabalin's CNS effects, elderly patients face heightened risk for delirium and falls.

Prescribing Algorithm

Step 1: Patient Assessment

• Age >65 years: Use lowest effective doses; consider alternatives
• Renal function: Reduce pregabalin dose if CrCl <60 mL/min 4
• Concurrent CNS depressants: Count all sedating medications (opioids, benzodiazepines, alcohol)
• History of substance abuse: Pregabalin is Schedule V; assess misuse risk 4

Step 2: Dosing Strategy

Pregabalin:

• Start 50 mg TID or 75 mg BID
• Titrate to 300 mg/day over 3-7 days
• Maximum 600 mg/day (though 300 mg often equally effective) 4

Cyclobenzaprine:

• Use 5 mg TID (lower dose preferred) 6
• Limit duration to 2-3 weeks for acute musculoskeletal conditions 7
• Avoid long-term use (>2-3 weeks) due to withdrawal symptoms and limited evidence 3

Step 3: Monitoring Protocol

First 1-2 weeks (critical period):

• Daily assessment of sedation level
• Fall risk evaluation
• Cognitive function checks in elderly
• Document any confusion or hallucinations

Ongoing:

• Reassess need for cyclobenzaprine weekly (should be short-term only)
• Monitor for constipation requiring laxatives
• Evaluate pregabalin efficacy at 4 weeks 4

Clinical Context and Evidence Quality

The evidence supporting this combination is indirect. No studies specifically evaluate pregabalin plus cyclobenzaprine, but:

1. Pregabalin's low interaction profile is well-established through FDA labeling and multiple pharmacokinetic studies 1, 2

2. Cyclobenzaprine is commonly combined with NSAIDs (ibuprofen, naproxen) for acute pain, showing efficacy but increased side effects 6, 8

3. Guidelines recommend pregabalin for neuropathic pain as first-line therapy 4, 9, while cyclobenzaprine is appropriate for acute musculoskeletal conditions with muscle spasm 7

Common Pitfalls to Avoid

1. Don't prescribe cyclobenzaprine long-term: It's indicated for acute conditions only; withdrawal symptoms (malaise, nausea, headache) occur after prolonged use 3

2. Don't ignore renal function: Pregabalin requires dose adjustment based on creatinine clearance 4

3. Don't combine with multiple CNS depressants: Each additional sedating medication compounds fall and respiratory depression risk 1

4. Don't use in patients on MAOIs: Cyclobenzaprine with MAOIs increases serotonin syndrome risk 3

5. Don't assume muscle relaxants actually relax muscles: Cyclobenzaprine's effects are nonspecific CNS depression, not true muscle relaxation 7

Alternative Considerations

If the combination produces excessive sedation:

• Reduce cyclobenzaprine to 5 mg once or twice daily (rather than TID)
• Consider topical NSAIDs (diclofenac gel) instead of cyclobenzaprine for localized pain 9
• Use pregabalin alone if neuropathic component predominates
• Switch to physical therapy and NSAIDs for musculoskeletal pain without neuropathic features

The combination is pharmacologically safe but requires vigilant monitoring for additive CNS depression, particularly in elderly patients or those on other sedating medications.